Noom 以具有竞争力的价格推出含有复合 semaglutide 的 GLP-1 Rx 计划。 Noom launches GLP-1 Rx program with compounded semaglutide at competitive prices.
Noom 推出了一项 GLP-1 Rx 计划，以具有竞争力的价格提供复合 semaglutide，这是 Novo Nordisk 的 Ozempic 和 Wegovy 的非品牌替代品——第一个月 149 美元，之后 279 美元。 Noom has launched a GLP-1 Rx program offering compounded semaglutide, an off-brand alternative to Novo Nordisk's Ozempic and Wegovy, at competitive prices—$149 for the first month and $279 afterward. 该方案强调为可持续减重而改变行为,并包括一个不计其数的选择。 The program emphasizes behavior modification for sustainable weight loss and includes a taper-off option. 然而,由于人工施用剂量,复合剂可能会造成安全风险,从而可能导致剂量过量。 However, compounded versions may pose safety risks due to manual dosing, leading to potential overdoses. 负担得起的减重药品市场越来越具有竞争力。 The market for affordable weight loss medications is becoming increasingly competitive.